• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia
【24h】

Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia

机译：ezetimibe单药治疗减少血脂血症患者血清活化因子乙酰水溶液的血清水平

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background:The combination of ezetimibe with statin therapy reduced cardiovascular events compared to statin monotherapy in IMPROVEIT study, and ezetimibe monotherapy attenuated atherosclerosis in basic study. We previously showed ezetimibe monotherapy was especially effective for metabolic syndrome (MetS) patients. We investigated the effects of ezetimibe monotherapy for high-density lipoprotein cholesterol (HDL-chol) function and platelet-activating factor acetylhydrolase (PAF-AH) activity.Methods:Forty-two patients who initially received ezetimibe (10 mg/day) without statin treatment for 16 weeks from January 2009 to August 2011 were enrolled. Patients were divided into MetS and non-MetS groups, and serum levels of lipids, PAF-AH, and HDL-chol efflux capacity (HDL-CEC) at baseline and after 16 weeks of treatment were investigated. Serum PAF-AH, HDL-associated PAF-AH (HDL-PAF-AH), and LDL-associated PAF-AH (LDL-PAF-AH) were measured.Results:In all patients, age, the percentages of males, and body mass index were 61.0 ± 8.8 years, 59.5% and 26.3 ± 3.4 kg/m2, respectively. Total cholesterol and low-density lipoprotein cholesterol (LDL-chol) were significantly decreased by ezetimibe monotherapy. Serum PAF-AH and LDL-PAF-AH were significantly decreased by ezetimibe monotherapy, whereas HDL-PAF-AH and HDL-CEC were not. There was no difference in the results of PAF-AH and HDL-CEC between MetS and non-MetS groups.Conclusions:Ezetimibe monotherapy might prevent coronary heart disease (CHD) regardless of the presence of MetS, because PAF-AH was independent risk factor for CHD.Copyright 2019, Tano et al.
机译：背景：与他汀类药物治疗的ezetimibe与他汀类药物单疗法的组合减少了心血管事件，以及ezetimibe单药治疗基础研究中的动脉粥样硬化。我们以前展示Ezetimibe单药治疗对于代谢综合征（Mets）患者特别有效。我们研究了Ezetimibe单药治疗高密度脂蛋白胆固醇（HDL-CHOL）功能和血小板活化因子乙酰水溶生素（PAF-AH）活性的影响。从2009年1月到2011年1月开始治疗16周。研究了患者的MET和非METS组，并研究了基线的血清脂质，PAF-AH和HDL-CEC）和HDL-CEC的HDL-CEC）和治疗16周后的血清水平。测得血清PAF-AH，HDL相关的PAF-AH（HDL-PAF-AH）和LDL相关的PAF-AH（LDL-PAF-AH）。结果：在所有患者中，年龄，男性的百分比和体重指数分别为61.0±8.8岁，分别为59.5％和26.3±3.4 kg / m 2。通过Ezetimibe单疗法显着降低了总胆固醇和低密度脂蛋白胆固醇（LDL-CHOL）。 ezetimibe单药治疗，血清PAF-αH和LDL-PAF-AH显着降低，而HDL-PAF-AH和HDL-CEC则不下降。 PAF-AH和HDL-CEC的结果没有差异，在METS和非METS组之间。结论：ezetimibe单药治疗可能预防冠心病（CHD），无论METS的存在如何，因为PAF-AH是独立的危险因素对于CHD.copyright 2019，Tano等人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号